A current perspective on stereotactic body radiation therapy for pancreatic cancer

Authors

Julian C. Hong

Brian G. Czito

Christopher G. Willett

Manisha Palta

Doi

10.2147/OTT.S99826

PMID: 27826200 · DOI: 10.2147/OTT.S99826 · Journal: OncoTargets and Therapy (2016)

TL;DR

This Duke University narrative review synthesizes the clinical evidence base for stereotactic body radiation therapy (SBRT) in pancreatic cancer (PMID:27826200). Across nine prospective studies the authors tabulate, SBRT delivered in 1–5 fractions yields 1-year local control rates of roughly 40–100% and median overall survival of 5.4–13.9 months in locally advanced pancreatic cancer (PAAD), with the lowest grade 3+ toxicities seen in the multi-institutional 33 Gy / 5-fraction gemcitabine+SBRT regimen (Herman et al, 49 patients, 79% 1-year local control, median OS 13.9 months, 2% acute and 6% late grade 3+ GI toxicity). The review covers technical implementation (fiducial placement, motion management, IMRT/VMAT planning, duodenal dose constraints) and highlights SMAD4/DPC4 loss and TGF-β pathway markers as candidate biomarkers for stratifying patients who may benefit from intensified local therapy.

Cohort & data

  • Narrative review — no primary cohort. Synthesizes nine prospective SBRT trials enrolling 10–49 patients each (total ~201 patients across the prospective table) plus retrospective borderline-resectable, neoadjuvant, and adjuvant SBRT series (PMID:27826200, Table 1).
  • Disease setting: predominantly locally advanced (unresectable) pancreatic adenocarcinoma (PAAD); also covers borderline resectable, neoadjuvant, and adjuvant settings.
  • Modalities reviewed: CyberKnife (Accuray, Sunnyvale, CA) frameless stereotactic radiosurgery and linac-based SBRT with IMRT, with one proton beam therapy Phase I/II series (Harvard, 50 patients, 25 Gy in 5 fractions neoadjuvantly).
  • Concurrent systemic therapy in the reviewed trials: gemcitabine (most frequent), 5-fluorouracil, and capecitabine; ongoing investigational combinations cited include FOLFIRINOX and gemcitabine/nab-paclitaxel.

Key findings

  • Single-fraction SBRT establishes local control but not survival. The Stanford Phase I dose-escalation trial (Koong et al, n=15, 15–25 Gy in 1 fraction) achieved 100% local control with 0% grade 3+ acute toxicity and 11-month median OS, but all 15 patients progressed distantly (PMID:27826200, Table 1).
  • Adding an IMRT boost raises local control at the cost of GI toxicity. Koong et al’s follow-up Phase II (n=16) of 45 Gy IMRT + 5-FU followed by 25 Gy/1 fx SBRT boost achieved 94% 1-year freedom from local recurrence but produced 13% grade 3+ acute toxicity (including grade 3 gastroparesis) and only 8.3-month median OS (PMID:27826200, Table 1).
  • Single-fraction SBRT with sequential gemcitabine produces high duodenal toxicity. Schellenberg et al (n=16) reported 100% 1-year local control and 11.4-month median OS with gemcitabine → 25 Gy/1 fx → gemcitabine, but late grade 2+ toxicity reached 47% with 5 duodenal ulcers, 1 stenosis, and 1 perforation (44% grade 2+ and 12.5% grade 3+ duodenal events) (PMID:27826200).
  • Tightening duodenal constraints reduces toxicity while preserving local control. A subsequent Stanford Phase II (n=20) using linac-based IMRT-SBRT with explicit duodenal limits (≤5% of duodenum receiving ≥22.5 Gy; ≤50% receiving ≥12.5 Gy; PTV margins 2–5 mm) achieved 94% 1-year local control with one grade 4 duodenal perforation (5%) and three grade 2 duodenal ulcers (15%) (PMID:27826200).
  • Multi-fraction SBRT is the current best-tolerated regimen. The multi-institutional Phase II at Johns Hopkins, Stanford, and MSKCC (Herman et al, n=49) delivered up to three weekly doses of gemcitabine followed by 33 Gy in 5 fractions and continued gemcitabine to progression: 79% 1-year local control, 13.9-month median OS, with only 1 (2%) acute and 3 (6%) late grade 3+ GI toxicities and significant improvement in pain scores (PMID:27826200, Table 1).
  • European fractionated regimens with larger margins did worse. The Danish Phase II (Høyer et al, n=22, 45 Gy/3 fx with abdominal compression and 5 mm transverse / 1 cm craniocaudal PTV margins, peritumoral edema in target) achieved only 57% 1-year local control with 79% grade 2+ acute GI toxicity and 5.4-month median OS, attributed to the larger treatment volumes (PMID:27826200, Table 1).
  • SBRT can convert borderline-resectable disease to resection. In Mellon et al’s retrospective series of 110 borderline-resectable patients (median 30 Gy to tumor and 40 Gy to vessel–tumor interface in 5 fractions), 51% underwent surgical resection with 96% margin-negative resection and 7% pathologic complete response (PMID:27826200). The Polistina CyberKnife series (n=23, 30 Gy/3 fx with induction + adjuvant gemcitabine) had 3 patients undergo resection — 2 R0 and 1 pathologic complete response — with 50% 1-year local control and zero grade 2+ toxicities.
  • Proton therapy in the neoadjuvant setting is feasible. The Harvard Phase I/II proton beam program (50 patients across studies, 25 Gy in 5 fractions with concurrent capecitabine) achieved 84% R0 resection in 39 resected patients with 4.1% grade 3 acute toxicity, 27-month median survival, and 16% locoregional recurrence (PMID:27826200).

Genes & alterations

  • SMAD4 (DPC4) loss — A Johns Hopkins rapid autopsy study cited in this review found that loss of SMAD4/DPC4 expression in the primary tumor correlates with greater propensity for metastatic disease (vs local-only progression) in stage III pancreatic cancer (PMID:27826200, citing Iacobuzio-Donahue 2009). SMAD4 status is being used as a stratification factor (alongside CA19-9) in ongoing cooperative-group SBRT trials.
  • TGFB1, TGFBR2, and SMAD4 polymorphisms — Within the same TGF-β/SMAD pathway, the review notes that high TGF-β1 plasma levels, the SMAD4 single-nucleotide polymorphism rs11354983, and high TGF-βR2/SMAD4 expression are correlated with poor outcomes in pancreatic cancer (PMID:27826200, citing Javle 2014).

Clinical implications

  • Multi-fraction SBRT (33 Gy / 5 fx) with gemcitabine is the current reference regimen for unresectable locally advanced pancreatic cancer based on the Herman et al multi-institutional data: 78% 1-year local control with manageable acute (2%) and late (6%) grade 3+ GI toxicity (PMID:27826200).
  • Duodenal dose constraints are essential. Recommended constraints from the multi-institutional protocol: proximal duodenum, stomach, and small bowel V15Gy <9 cc, V20Gy <3 cc, V33Gy <1 cc; liver V12Gy <50%; combined kidneys V12Gy <75%; spinal cord V8Gy <1 cc.
  • Borderline-resectable disease is a candidate setting for neoadjuvant SBRT with high R0 conversion rates (84–96% margin-negative among resected patients in cited retrospective series).
  • SMAD4/DPC4 status and CA19-9 are emerging stratification biomarkers for selecting patients most likely to benefit from local intensification (vs systemic therapy escalation).
  • Pre-SBRT PET parameters (SUVmax, metabolic tumor volume, total lesion glycolysis) and laboratory markers (albumin, neutrophil–lymphocyte ratio) correlate with progression-free and overall survival, supporting their use in patient selection.
  • No prospective head-to-head SBRT vs conventionally fractionated chemoradiation comparison exists as of this 2016 review — the authors flag this as a major evidence gap.

Limitations & open questions

  • No randomized comparison vs conventional chemoradiation. The authors explicitly state that there has been no prospective comparison of SBRT versus conventionally fractionated chemoradiation (PMID:27826200).
  • Distant progression dominates outcomes. Across nearly every prospective trial, distant metastatic progression — not local failure — drives mortality, indicating that even excellent local control with SBRT cannot rescue inadequate systemic therapy.
  • Wide variability in 1-year local control (40–100%) across nominally similar SBRT regimens reflects un-standardized target definition, motion management, and dose constraints. The Danish series (57% local control, 79% grade 2+ acute toxicity with larger PTV margins and peritumoral edema in target) illustrates how technique variation drives outcomes.
  • Limited prospective data in the neoadjuvant, borderline-resectable, and adjuvant settings — most evidence in these populations is retrospective.
  • Open biomarker questions: Whether SMAD4/DPC4 status, TGF-β pathway activation, pre-SBRT PET metrics (SUVmax, metabolic tumor volume, total lesion glycolysis), or laboratory markers (albumin, neutrophil–lymphocyte ratio) can prospectively select patients for SBRT intensification remains untested in randomized trials.
  • Combination strategies untested: Ongoing trials combine SBRT with FOLFIRINOX (NCT01992705, NCT01446458), gemcitabine/nab-paclitaxel (NCT02318095), and immunotherapy (allogeneic GM-CSF–secreting tumor vaccines, NCT02405585). Whether SBRT acts as an immunosensitizer in pancreatic cancer is unproven.

Citations from this paper used in the wiki

  • “An emerging local modality is stereotactic body radiation therapy (SBRT), which uses image-guided, conformal, high-dose radiation. SBRT has demonstrated promising local control rates and resultant quality of life with acceptable rates of toxicity.” (Abstract)
  • “Forty-nine patients received 33 Gy in five fractions with up to three doses of gemcitabine weekly before SBRT, followed by additional gemcitabine until disease progression… Study results were consistent with previously reported studies, with 79% local control at 1 year and a median overall survival of 13.9 months. A lower rate of toxicity was reported versus single fraction treatment, with one acute (2%) and three late (6%) grade 3+ GI toxicities.” (Section: Clinical evolution of SBRT)
  • “A rapid autopsy study from Johns Hopkins showed a correlation between the loss of SMAD4/DPC4 expression and greater propensity for metastatic disease. Within the same pathway, high transforming growth factor-β1 plasma levels, the SMAD4 single-nucleotide polymorphism rs11354983, and high transforming growth factor-βR2/SMAD4 expression are similarly correlated with poor outcomes. SMAD4 is a stratification factor, alongside CA19-9 levels, in ongoing cooperative group studies.” (Section: Future directions)
  • “The normal tissue constraints described in this study are as follows: proximal duodenum, stomach, and small bowel with V15 Gy <9 cc, V20Gy <3 cc, and V33 Gy <1 cc; liver V12 Gy <50%; combined kidneys V12 <75%; and spinal cord V8 Gy <1 cc.” (Section: Treatment planning)
  • “At present, there has been no prospective comparison of SBRT versus conventionally fractionated chemoradiation. The delivery of high-dose, highly conformal, and precise radiotherapy enables ablative therapy to unresectable pancreatic lesions, with data suggesting local control rates of at least 78%.” (Conclusion)

This page was processed by crosslinker on 2026-05-14.